SEARCH

SEARCH BY CITATION

References

  • 1
    Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol. 2003; 163: 7019.
  • 2
    Halbfinger D. A nation challenged: notebooks; nervous in New Jersey. New York City, NY: New York Times, 2001. p.10.
  • 3
    Bresnitz E, DiFerdinando G. Lessons from the anthrax attacks of 2001: the New Jersey experience. Clin Occup Environ Med. 2003; 2: 22752.
  • 4
    GAO. Bioterrorism: public health response to anthrax incidents of 2001. Washington, DC: Office UGA, editor; 2003.
  • 5
    Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med. 1999; 341: 81526.
  • 6
    Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci USA. 1993; 90: 10198201.
  • 7
    Prince AS. The host response to anthrax lethal toxin: unexpected observations. J Clin Invest. 2003; 112: 6568.
  • 8
    Pitt ML, Little SF, Ivins BE, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine. 2001; 19: 476873.
  • 9
    Ivins BE, Pitt ML, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998; 16: 11418.
  • 10
    Boyer AE, Quinn CP, Beesley CA, et al. Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax. J Infect Dis. 2011; 204: 13217.
  • 11
    Liu S, Crown D, Miller-Randolph S, et al. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci USA. 2009; 106: 124249.
  • 12
    Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA. 2003; 100: 51704.
  • 13
    Bonuccelli G, Sotgia F, Frank PG, et al. ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis’ three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol Cell Physiol. 2005; 288: C140210.
  • 14
    Langer M, Duggan ES, Booth JL, et al. Bacillus anthracis lethal toxin reduces human alveolar epithelial barrier function. Infect Immun. 2012; 80: 437487.
  • 15
    Rmali KA, Al-Rawi MA, Parr C, et al. Upregulation of tumour endothelial marker-8 by interleukin-1beta and its impact in IL-1beta induced angiogenesis. Int J Mol Med. 2004; 14: 7580.
  • 16
    Liu S, Miller-Randolph S, Crown D, et al. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe. 2010; 8: 45562.
  • 17
    Pickering AK, Merkel TJ. Macrophages release tumor necrosis factor alpha and interleukin-12 in response to intracellular Bacillus anthracis spores. Infect Immun. 2004; 72: 306972.
  • 18
    Mabry R, Brasky K, Geiger R, et al. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol. 2006; 13: 6717.
  • 19
    Kobiler D, Weiss S, Levy H, et al. Protective antigen as a correlative marker for anthrax in animal models. Infect Immun. 2006; 74: 58716.
  • 20
    Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994; 266: 12028.
  • 21
    Brookmeyer R, Blades N, Hugh-Jones M, et al. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics. 2001; 2: 23347.
  • 22
    Grinberg LM, Abramova FA, Yampolskaya OV, et al. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod Pathol. 2001; 14: 48295.
  • 23
    Lyons CR, Lovchik J, Hutt J, et al. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun. 2004; 72: 48019.
  • 24
    Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001; 7: 93344.
  • 25
    Mina B, Dym JP, Kuepper F, et al. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA. 2002; 287: 85862.
  • 26
    Hoffmaster AR, Hill KK, Gee JE, et al. Characterization of Bacillus cereus isolates associated with fatal pneumonias: strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J Clin Microbiol. 2006; 44: 335260.
  • 27
    Avashia SB, Riggins WS, Lindley C, et al. Fatal pneumonia among metalworkers due to inhalation exposure to Bacillus cereus Containing Bacillus anthracis toxin genes. Clin Infect Dis. 2007; 44: 4146.
  • 28
    Wright AM, Beres SB, Consamus EN, et al. Rapidly progressive, fatal, inhalation anthraxlike infection in a human: case report, pathogen genome sequencing, pathology, and coordinated response. Arch Pathol Lab Med. 2011; 135: 144759.
  • 29
    Moayeri M, Haines D, Young HA, et al. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest. 2003; 112: 67082.
  • 30
    Dumas EK, Cox PM, Fullenwider CO, et al. Anthrax lethal toxin-induced gene expression changes in mouse lung. Toxins. 2011; 3: 111130.
  • 31
    Firoved AM, Miller GF, Moayeri M, et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol. 2005; 167: 130920.
  • 32
    Sweeney DA, Cui X, Solomon SB, et al. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis. 2010; 202: 188596.
  • 33
    Cui X, Li Y, Li X, et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis. 2007; 195: 57280.
  • 34
    Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun. 2004; 72: 4309.
  • 35
    Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet. 2006; 38: 2404.
  • 36
    Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982; 46: 8694.
  • 37
    Ringertz SH, Hoiby EA, Jensenius M, et al. Injectional anthrax in a heroin skin-popper. Lancet. 2000; 356: 15745.
  • 38
    Booth MG, Hood J, Brooks TJ, et al. Anthrax infection in drug users. Lancet. 2010; 375: 13456.
  • 39
    Radun D, Bernard H, Altmann M, et al. Preliminary case report of fatal anthrax in an injecting drug user in North-Rhine-Westphalia, Germany, December 2009. Euro Surveill. 2010; 15, pii=19464, http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19464.
  • 40
    Holzmann T, Frangoulidis D, Simon M, et al. Fatal anthrax infection in a heroin user from southern Germany, June 2012. Euro Surveill. 2012; 17, pii=20204, http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20204.
  • 41
    Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, et al. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol. 2006; 169: 43344.
  • 42
    Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013; 34: 12936.
  • 43
    Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003; 16: 437.
  • 44
    Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA. 2001; 286: 25549.
  • 45
    Zhao H, Heard SO, Mullen MT, et al. An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest Physicians/American Thoracic Society/Surgical Infection Society sepsis definition. Crit Care Med. 2012; 40: 17006.
  • 46
    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39: 165228.
  • 47
    de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun. 2010; 2: 42230.
  • 48
    van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis. 2011; 24: 2738.
  • 49
    Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol. 2012; 34: 16779.
  • 50
    Semeraro N, Biondi A, Lorenzet R, et al. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology. 1983; 50: 52935.
  • 51
    Taylor FB Jr, Chang A, Ruf W, et al. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991; 33: 12734.
  • 52
    Taylor FB, Haddad PA, Hack E, et al. Two-stage response to endotoxin infusion into normal human subjects: correlation of blood phagocyte luminescence with clinical and laboratory markers of the inflammatory, hemostatic response. Crit Care Med. 2001; 29: 32634.
  • 53
    van Deventer SJ, Buller HR, ten Cate JW, et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990; 76: 25206.
  • 54
    Chung MC, Jorgensen SC, Popova TG, et al. Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection. J Med Microbiol. 2009; 58: 73744.
  • 55
    Park JM, Ng VH, Maeda S, et al. Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med. 2004; 200: 164755.
  • 56
    Chung MC, Popova TG, Jorgensen SC, et al. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J Biol Chem. 2008; 283: 953142.
  • 57
    Triantafilou M, Uddin A, Maher S, et al. Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers. Cell Microbiol. 2007; 9: 288092.
  • 58
    Iyer JK, Coggeshall KM. Cutting edge: primary innate immune cells respond efficiently to polymeric peptidoglycan, but not to peptidoglycan monomers. J Immunol. 2011; 186: 38415.
  • 59
    Iyer JK, Khurana T, Langer M, et al. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun. 2010; 78: 241828.
  • 60
    Langer M, Malykhin A, Maeda K, et al. Bacillus anthracis peptidoglycan stimulates an inflammatory response in monocytes through the p38 mitogen-activated protein kinase pathway. PLoS ONE. 2008; 3: e3706.
  • 61
    Majcherczyk PA, Rubli E, Heumann D, et al. Teichoic acids are not required for Streptococcus pneumoniae and Staphylococcus aureus cell walls to trigger the release of tumor necrosis factor by peripheral blood monocytes. Infect Immun. 2003; 71: 370713.
  • 62
    Myhre AE, Stuestol JF, Dahle MK, et al. Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain. Infect Immun. 2004; 72: 13117.
  • 63
    Cui X, Su J, Li Y, et al. Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med. 2010; 36: 14856.
  • 64
    Sweeney DA, Hicks CW, Cui X, et al. Anthrax infection. Am J Respir Crit Care Med. 2011; 184: 133341.
  • 65
    Sun D, Raisley B, Langer M, et al. Anti-peptidoglycan antibodies and fcgamma receptors are the key mediators of inflammation in gram-positive sepsis. J Immunol. 2012; 189: 242331.
  • 66
    Elinav E, Strowig T, Henao-Mejia J, et al. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011; 34: 66579.
  • 67
    Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. J Infect Public Health. 2010; 3: 98105.
  • 68
    Klempner MS, Talbot EA, Lee SI, et al. Case records of the Massachusetts General Hospital. Case 25–2010. A 24-year-old woman with abdominal pain and shock. N Engl J Med. 2010; 363: 76677.
  • 69
    Mazumdar S. Raxibacumab. mAbs. 2009; 1: 5318.